• The present invention relates generally to diagnostic and prognostic assays. In particular, the present invention relates to the use of C4 activation fragments as diagnostic and prognostic markers for lung cancer.
  • C4 activation fragments may also be useful for estimating the risk of lung cancer and for deciding whether to initiate a medical regimen and for determining whether the medical regimen initiated is effective. 

Icono propiedad intelectual Intellectual Property

New Patent application filed (WO2013143940).